Explanipedia

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience Open

Philippe Moreau, Cyrille Hulin, Alexis Talbot, Hélène Demarquette, Léo Caillot , et al. · 2025

Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study Open

Titouan Cazaubiel, Pascale Olivier, Bruno Royer, Denis Caillot, Arthur Bobin , et al. · 2025

Managing multiple myeloma (MM) patients receiving advanced (four or more) lines of treatment is a complex challenge. Therefore, real-world data are essential to better understand and address the medical need of this challenging population.…

Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort Open

Cyrille Hulin, Karim Belhadj Merzoug, Bruno Royer, Denis Caillot, Arthur Bobin , et al. · 2025

This real-world study confirms carfilzomib effectiveness at both dosing frequencies. K triplets resulted in long survivals and Kd remained satisfactory to treat heavily pretreated patients.

Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study Open

Alexis Talbot, Cyrille Hulin, Aurore Perrot, Margaret Macro, Karim Belhadj Merzoug , et al. · 2025

These results of aCD38 retreatment in a large sample of real-life patients (n = 286) in extensively pretreated patients show that retreatment may be a meaningful strategy for aCD38 sensitive patients. These findings need to be investigated…

Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐CD38 Antibodies: The EMMY Cohort From 2017 to 2020 Open

Laure Vincent, Olivier Decaux, Aurore Perrot, Bruno Royer, Thomas Chalopin , et al. · 2025

Aims/Background Recent agents have profoundly reshaped the multiple myeloma (MM) landscape. Their real‐world impacts need to be assessed over the long term. Methods EMMY is a non‐interventional, prospective dynamic cohort, conducted in Fra…

Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM Open

Florent Malard, Arthur Bobin, Myriam Labopin, Lionel Karlin, Laurent Frenzel , et al. · 2024

Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program Open

Aurore Perrot, Cyrille Hulin, Ariane Boumendil, Hamza Manjra, A. Lévêque , et al. · 2024

International audience

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial Open

Xavier Leleu, Cyrille Hulin, Jérôme Lambert, Arthur Bobin, Aurore Perrot , et al. · 2024

Posterior reversible encephalopathy syndrome (PRES) and myeloma Open

Ricardos Ghanem, Sylvie Glaisner, Arthur Bobin, Anne‐Marie Ronchetti, Sophie Cereja , et al. · 2023

Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms Open

Thomas Systchenko, Jean‐Claude Chomel, Pilar Gallego‐Hernanz, Niels Moya, Déborah Desmier , et al. · 2023

Summary Myeloproliferative neoplasms in blastic phase (MPN‐BP) have a dreadful prognosis. We report the characteristics and outcomes of five MPN‐BP patients treated with a never‐before‐described combination of azacytidine and venetoclax (t…

Hairy cell leukemia with isolated bone lesions Open

Laura Cailly, Cécile Gruchet, Elsa Maître, Stéphanie Guidez, Vincent Delwail , et al. · 2023

Key Clinical Message 18 F‐FDG PET/CT has clinical relevance in HCL at diagnosis and for the follow‐up of patients treated, especially in case of atypical presentations such as bone involvements (which are probably underestimated) and poor …

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study Open

Alexis Talbot, Arthur Bobin, Léa Tabone, Jérôme Lambert, C Boccaccio , et al. · 2023

Belantamab mafodotin (BM) is an anti-BCMA antibody-drug conjugate (GSK2857916) that represents an alternative option in multiple myeloma. We sought to assess the efficacy and safety of BM in a real-world setting in patients who benefited f…

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma Open

Aurélia Chacon, Xavier Leleu, Arthur Bobin · 2023

The treatment of multiple myeloma (MM) has greatly evolved these past few years. Recent advances in therapeutics have largely benefited elderly patients now renamed “non-transplant-eligible” (NTE) patients. Since the 1960s, and for several…

Hairy cell leukemia with isolated bone lesions Open

Laura Cailly, Cécile Gruchet, Elsa Maître, Stéphanie Guidez, Vincent Delwail , et al. · 2023

Bone lesions are rarely reported in Hairy Cell Leukemia (HCL). We report two BRAFV600E mutated HCL patients presented bone lesions at foreground, poor bone marrow involvement and the important role 18F-FDG PET/CT played in their management…

Recent advances in the treatment of multiple myeloma: a brief review Open

Arthur Bobin, Xavier Leleu · 2022

The recent history of multiple myeloma has been marked by tremendous advances in the treatments available, which have ultimately improved the patients' survival. Immune-based therapies, starting with the emergence of anti-CD38 monoclonal a…

P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01 Open

Arthur Bobin, Salomon Manier, Jean Keizer, L. Karlin, A. Perrot , et al. · 2022

Background: High risk (HR) cytogenetics remains of poor prognosis, particularly in the RRMM setting. IFM 2010-02, Pd in advanced HR RRMM, had demonstrated limited activity with no addition of a proteasome inhibitor (PI), and a good safety …

Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article Open

Arthur Bobin, Cécile Gruchet, Stéphanie Guidez, Hélène Gardeney, Laly Nsiala Makunza , et al. · 2021

Novel treatments are needed to address the lack of options for patients with relapsed or refractory multiple myeloma. Even though immunotherapy-based treatments have revolutionized the field in recent years, offering new opportunities for …

Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients Open

Hélène Gardeney, Arthur Bobin, Cécile Gruchet, Florence Sabirou, Anthony Lévy , et al. · 2020

The multiple myeloma (MM) non transplant eligible (NTE) population is growing in line with the aging of the population in Western countries. Historically, this population has been known for having a greater risk of treatment related toxici…

Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020 Open

Arthur Bobin, Évelyne Liuu, Niels Moya, Cécile Gruchet, Florence Sabirou , et al. · 2020

The survival rate of multiple myeloma (MM) patients has drastically increased recently as a result of the wide treatment options now available. Younger patients truly benefit from these innovations as they can support more intensive treatm…

Disseminated form of the Kaposi sarcoma in HIV-negative patient associated with Hodgkin’s lymphoma Open

Victoria Tutaeva, Arthur Bobin, M R Ovsiannikova, Mariya Bulgakova, Yurii Miroslavovich Kuchma , et al. · 2020

We report a case of a 35-year-old, non-HIV-infected male diagnosed simultaneously with a disseminated form of Kaposi’s sarcoma (KS; skin, stomach and colon are involved) and Hodgkin’s lymphoma. There is no sign of changes in the immune sta…

Score LLC IPS-E : un nouvel outil pratique pour la surveillance des patients avec une leucémie lymphoïde chronique de stade précoce Open

Arthur Bobin, Xavier Leleu, Cécile Tomowiak · 2020

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma Open

Arthur Bobin, Hélène Gardeney, Florence Sabirou, Cécile Gruchet, Anthony Lévy , et al. · 2020

As the global population is aging and survival in multiple myeloma (MM) is increasing, treating older MM patients, redefined as non-transplant eligible (NTE), is becoming more frequent. Yet, treating these patients remains a real challenge…

PS1406 WEEKLY CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE UNTIL PROGRESSION IN RELAPSED REFRACTORY MULTIPLE MYELOMA Open

Cécile Gruchet, Valentine Richez, Stéphanie Guidez, Cécile Tomowiak, Guillemette Fouquet , et al. · 2019

Background: Carfilzomib, Lenalidomide and Dexamethasone association (KRd) has led to approval in early RRMM. On ASPIRE International phase 3 study Carfilzomib was used on a twice a week basis at 27 mg/m 2 and limited to 18 months exposure.…

PB1827 LENALIDOMIDE AND RITUXIMAB COMBINED WITH CEP CHEMOTHERAPY (R2CEP) FOR PATIENTS WITH RELAPSED B-CELL LYMPHOMA. Open

Stéphanie Guidez, Cécile Gruchet, Cécile Tomowiak, Arthur Bobin, C. Debiais , et al. · 2019

Background: Patients with relapse or refractory (R/R) B-cell Non Hodgkin Lymphoma (B-NHL), especially DLBCL, have a poor prognostic mainly because of the difficulty of effective treatment. In patients relapsed after intensive chemotherapy …

PF607 MAINTENANCE WITH WEEKLY CARFILZOMIB IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (IFM 2012–03) Open

Arthur Bobin, Guillemette Fouquet, Alain Duhamel, Lionel Karlin, Brigitte Kolb , et al. · 2019

Background: Continuous therapy, such as maintenance, appears to be a major therapeutic change in multiple myeloma, improving response rate and overall survival. Novel agents widen the range of treatment options, but still Lenalidomide (IMI…

PS1412 POMALIDOMIDE 3RD LINE VERSUS 4TH LINE FOR IN EARLY RELAPSED REFRACTORY MULTIPLE MYELOMA Open

Cécile Gruchet, Stéphanie Guidez, Cécile Tomowiak, Guillemette Fouquet, Antoine Machet , et al. · 2019

Background: Pomalidomide in association with dexamethasone is approved for relapsed and refractory Mutiple Myeloma (RRMM) in 3 rd line and beyond based on the multicenter international phase 3MM‐003 study that demonstrated greater efficacy…

Response to pneumococcal vaccination in multiple myeloma Open

Loïc Renaud, Susanna Schraen, Guillemette Fouquet, Stéphanie Guidez, Hélène Demarquette , et al. · 2019

Background Streptococcus pneumoniae infection causes morbidity and mortality in multiple myeloma patients. Pneumococcal vaccination is commonly given to immunocompromised myeloma patients; however response data are sparse. Here, we present…

Long‐term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98‐LEDGF rearrangement Open

Maria Pilar Gallego Hernanz, José Miguel Torregrosa Diaz, Nathalie Sorel, Arthur Bobin, Elodie Dindinaud , et al. · 2019

A large variety of molecular rearrangements of the NUP98 gene have been described in the past decades (n = 72), involving fusion partners coding for different transcription factors, chromatin modifying enzymes, as well as various cytosolic…

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma Open

Guillemette Fouquet, Stéphanie Guidez, Valentine Richez, Anne‐Marie Stoppa, Christophe Le Tourneau , et al. · 2018

This study suggests that egression of tumor cells to the blood stream can represent a novel therapeutic strategy for MM. However, because of significant hematological toxicity, this study had to be discontinued. Further studies are needed …

Arthur Bobin YOU? Author Swipe